Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	323	1p32.1	TACSTD2	tumor associated calcium signal transducer 2
Mouse	1	317	6 C1	Tacstd2	tumor-associated calcium signal transducer 2
Rat	1	317	4q31	Tacstd2	tumor-associated calcium signal transducer 2

Previous and Unofficial Names

M1S1 | EGP-1 | TROP2 | TROP-2 | GA733-1 | RS7 antigen [3] | tumor-associated calcium signal transducer 2

Database Links
Alphafold	P09758 (Hs), Q8BGV3 (Mm), Q6P9Z6 (Rn)
CATH/Gene3D	4.10.800.10
ChEMBL Target	CHEMBL3856163 (Hs)
Ensembl Gene	ENSG00000184292 (Hs), ENSMUSG00000051397 (Mm), ENSRNOG00000007740 (Rn)
Entrez Gene	4070 (Hs), 56753 (Mm), 494343 (Rn)
Human Protein Atlas	ENSG00000184292 (Hs)
KEGG Gene	hsa:4070 (Hs), mmu:56753 (Mm), rno:494343 (Rn)
OMIM	137290 (Hs)
Pharos	P09758 (Hs)
RefSeq Nucleotide	NM_002353 (Hs), NM_020047 (Mm), NM_001009540 (Rn)
RefSeq Protein	NP_002344 (Hs), NP_064431 (Mm), NP_001009540 (Rn)
UniProtKB	P09758 (Hs), Q8BGV3 (Mm), Q6P9Z6 (Rn)
Wikipedia	TACSTD2 (Hs)

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols		Click column headers to sort
Antibody Sp. Action Value Parameter Reference hIMB1636-MMAE Hs Binding 9.1 pKd 4 ⤷ pKd 9.1 (Kd 7x10-10 M) [4] Description: Binding affinity for recombinant antigen sacituzumab govitecan Hs Binding - - 1 ⤷ [1] datopotamab deruxtecan Hs Binding - - 2 ⤷ [2]

Clinically-Relevant Mutations and Pathophysiology
Disease:  Corneal dystrophy, gelatinous drop-like; GDLD Synonyms: Gelatinous drop-like corneal dystrophy [Orphanet: ORPHA98957] OMIM: 204870 Orphanet: ORPHA98957
Disease:  Honey-droplet corneal dystrophy Orphanet: ORPHA98958

General Comments

TROP2 is a an antigen that is overexpressed on the surface of tumours of the lung, breast, pancreas and other organs. Elevated TROP2 expression is associated with poor prognosis. The first anti-TROP2 ADC to be approved was Immunomedics' sacituzumab govitecan (Trodelvy®) in April 2020. AstraZeneca, in partnership with Daiichi Sankyo, have anti-TROP2 ADC datopotamab deruxtecan (DS-1062) in advanced clinical development. DS-1062 is a humanised mAb conjugated to the exatecan derivative MAAA1181a (a.k.a. DXd).